Merck & Co., Inc. (MRK)
| Market Cap | 209.31B |
| Revenue (ttm) | 63.92B |
| Net Income (ttm) | 17.43B |
| Shares Out | 2.52B |
| EPS (ttm) | 6.88 |
| PE Ratio | 12.09 |
| Forward PE | 9.24 |
| Dividend | $3.24 (3.90%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 11,754,712 |
| Open | 84.18 |
| Previous Close | 83.26 |
| Day's Range | 82.99 - 84.64 |
| 52-Week Range | 75.93 - 134.63 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 115.93 (+39.37%) |
| Earnings Date | Apr 24, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $115.93, which is an increase of 39.37% from the latest price.
News
Top 10 High-Yield Dividend Stocks To Consider In May 2025
Q2 2025 began with market volatility due to tariff announcements, resulting in SPY losing 0.87% and VYM declining by 3.54%. Since inception, my watchlist has a CAGR of 14.61%, outperforming SPY and VY...
3 Names I Picked Up In The Latest Market Slump
When the market is reaching toward all-time highs, I tend to start building a cash pile. When the market starts to get quite volatile and brings declines, that can create opportunities for putting som...
Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda
The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on New $1 billion Biologics Center of Excellence in Wilmington, Delaware.
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports
U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall St...
Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
2 Must-Own Dividends At Bargain Basement Prices
April's market volatility has created dividend bargains, allowing investors to pick high-quality blue-chip stocks with strong balance sheets and long-term return potential. Merck, trading at a low P/E...
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (p...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Merck & Co. Inc‘s MRK M&A efforts will continue.
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Corporate Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Ch...
Stocks on the Move: Merck, Gilead Sciences, P&G, PG&E Corp, Adobe and the URNM
The Investment Committee debate how to trade some stocks on the move today.
Cramer's Mad Dash: Merck
Jim Cramer breaks down why he's keeping an eye on shares of Merck.
Merck absorbs $200 million in tariff costs into its earnings and full-year outlook
Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly earnings beats and held firm with its full-year outlook despite expected t...
Merck Cuts 2025 View on Tariffs, Charges
Merck's first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tarif...
Merck posts higher profit, puts tariffs cost at $200 million
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China d...
Merck lowers profit outlook, partly due to $200 million expected tariff hit
Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date. The company said the expec...
Merck Announces First-Quarter 2025 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Financial Results.
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.
The Setup: Chipotle, United Rentals, Merck and Pepsi
The Investment Committee give you The Setup on some key names reporting this week.
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I mai...
Merck & Co.: Pipeline Resilience To Unlock Value
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, ...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...